Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Therapies
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le jeudi 30 mai 2019
Doi : 10.1016/j.therap.2019.05.001
Received : 6 January 2019 ;  accepted : 9 May 2019
Profil d’acceptabilité de l’antimoniate de méglumine (Glucantime®) par voie parentérale chez le nourrisson traité pour leishmaniose cutanée
Safety profile of parenteral meglumine antimoniate (Glucantime®) in infants treated for cutaneous leishmaniasis
 

Fatma Frikha , Sonia Boudaya, Emna Bahloul, Meriem Amouri, Hamida Turki
 Service de dermatologie vénéréologie, hôpital Hédi Chaker, avenue Ain, 3089 Sfax, Tunisie 

Auteur correspondant.

Mots clés : Leishmaniose cutanée, Glucantime, Antimoniate de méglumine, Effets indésirables, Nourrisson, Enfant

Keywords : Cutaneous leishmaniasis, Glucantime, Meglumine antimoniate, Side effects, Infant, Children




© 2019  Société française de pharmacologie et de thérapeutique@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline